Raphael Pharmaceutical (RAPH) Other financing activities (2025)

Raphael Pharmaceutical's (RAPH) quarterly Other financing activities came in at $1000.0 in Q4 2025, down 97.44% quarter-over-quarter from $39000.0 in Q3 2025.

Raphael Pharmaceutical (RAPH) Other financing activities (2025) Analysis & Trends

Raphael Pharmaceutical has disclosed Other financing activities across 1 years of filings, most recently posting $1000.0 for Q4 2025.

  • Other financing activities for Q4 2025 came in at $1000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $245000.0 (changed N/A YoY), and the FY2025 annual result was $245000.0, down 30.0% from the prior year.
  • Other financing activities came in at $1000.0 for Q4 2025 at Raphael Pharmaceutical, down from $39000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $197000.0 in Q1 2025 to a low of $1000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Raphael Pharmaceutical - - -

Historic Data

Download Data
DateValue
Dec 31, 2025 1,000.00
Dec 31, 2025 1,000.00
Sep 30, 2025 39,000.00
Sep 30, 2025 39,000.00
Jun 30, 2025 8,000.00
Jun 30, 2025 8,000.00
Mar 31, 2025 197,000.00
Mar 31, 2025 197,000.00